3561 Results

People

  1. Motzer
    Motzer
  2. Saltz
    Saltz
  3. Hudis
    Hudis
  4. O'Reilly
    O'Reilly
  5. Gonen
    Gonen
  6. Kris
    Kris
  7. D'Angelica
    D'Angelica
  8. Jarnagin
    Jarnagin
  9. Scher
    Scher
  10. Ilson
    Ilson

Groups

  1. Department of Medicine (1663)
  2. Solid Tumor Oncology Division (1185)
  3. Surgery (839)
  4. Survivorship Research (593)
  5. Hematologic Malignancies, Division of (475)
  6. Center for Hematologic Malignancies (461)
  7. GSK Faculty (449)
  8. Epidemiology and Biostatistics (352)
  9. Gastrointestinal Oncology Service (324)
  10. Population Sciences Research Program (305)
  1. "antineoplastic agent"
Formats
  1. Journal Article (3226)
  2. Review (157)
  3. Editorial (63)
  4. Conference Paper (35)
  5. Research Letter (32)
  6. Guidelines (18)
  7. Correspondence (14)
  8. Miscellaneous (8)
  9. Meeting Abstract (6)
  10. Book Section (2)
Groups
  1. Department of Medicine (1663)
  2. Solid Tumor Oncology Division (1185)
  3. Surgery (839)
  4. Survivorship Research (593)
  5. Hematologic Malignancies, Division of (475)
  6. Center for Hematologic Malignancies (461)

More Groups

People
  1. Robert Motzer (92)
  2. Leonard Saltz (72)
  3. Clifford Hudis (70)
  4. Eileen O'Reilly (65)
  5. Mithat Gonen (63)
  6. Mark Kris (58)

More People

Years
  1. 2025 (114)
  2. 2024 (308)
  3. 2023 (226)
  4. 2022 (202)
  5. 2021 (45)
  6. 2020 (99)

More Years

Publications
  1. Journal of Clinical Oncology (297)
  2. Annals of Surgical Oncology (113)
  3. Clinical Cancer Research (90)
  4. New England Journal of Medicine (74)
  5. Cancer (72)
  6. Journal of the National Comprehensive Cancer Network (72)

More Publications

Publishers
  1. Elsevier Inc. (466)
  2. American Society of Clinical Oncology (337)
  3. Springer (321)
  4. Elsevier Science, Inc. (187)
  5. Wiley Blackwell (183)
  6. Nature Publishing Group (170)

More Publishers

Results (3561)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ASO Author Reflections: Immune-related adverse events during neoadjuvant chemoimmunotherapy for triple-negative breast cancer may influence time to adjuvant radiation
    Editorial

    Myers, S. P.; Downs-Canner, S. M.
    Annals of Surgical Oncology (2024)

    Fulltext@MSK | Save
  • Impact of neoadjuvant chemoimmunotherapy on surgical outcomes and time to radiation in triple-negative breast cancer
    Journal Article

    Myers, S. P.; Sevilimedu, V.; Jones, V. M.; Abuhadra, N.; Montagna, G.; Plitas, G.; Morrow, M.; Downs-Canner, S. M.
    Annals of Surgical Oncology (2024)

    Fulltext@MSK | Save
  • Characterizing disparities in receipt of palliative care for Asian Americans, Native Hawaiians, and Pacific Islanders with metastatic cancer in the United States
    Journal Article

    Kohli, K.; Kohli, M.; Jain, B.; Swami, N.; Ranganathan, S.; Chino, F.; Iyengar, P.; Yerramilli, D.; Dee, E. C.
    Supportive Care in Cancer (2024)

    Fulltext@MSK | Save
  • Multi-modality imaging parameters that predict rapid tumor regression in head and neck radiotherapy
    Journal Article

    Aliotta, E.; Paudyal, R.; Diplas, B.; Han, J.; Hu, Y. C.; Hun Oh, J.; Hatzoglou, V.; Jensen, N.; Zhang, P.; Aristophanous, M.; more...
    Physics and Imaging in Radiation Oncology (2024)

    Fulltext@MSK | Save
  • Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma
    Journal Article

    Till, J. E.; McDaniel, L.; Chang, C.; Long, Q.; Pfeiffer, S. M.; Lyman, J. P.; Padrón, L. J.; Maurer, D. M.; Yu, J. X.; Spencer, C. N.; more...
    Nature Communications (2024)

    Fulltext@MSK | Save
  • RB1 genetic alterations in estrogen receptor–positive breast carcinomas: Correlation with neuroendocrine differentiation
    Journal Article

    Schwartz, C. J.; Marra, A.; Selenica, P.; Gazzo, A.; Tan, K.; Ross, D.; Razavi, P.; Chandarlapaty, S.; Weigelt, B.; Reis-Filho, J. S.; more...
    Modern Pathology (2024)

    Fulltext@MSK | Save
  • Phase I and randomized phase II study of ruxolitinib with frontline neoadjuvant therapy in advanced ovarian cancer: An NRG Oncology Group Study
    Journal Article

    Landen, C. N.; Buckanovich, R. J.; Sill, M. W.; Mannel, R. S.; Walker, J. L.; Disilvestro, P. A.; Mathews, C. A.; Mutch, D. G.; Hernandez, M. L.; Martin, L. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Ocular side effects of anticancer agents used in the treatment of gynecologic cancers
    Review

    Crowley, F.; Broderick, S.; Francis, J. H.; O'Cearbhaill, R. E.; Canestraro, J.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Single-cell decoding of drug induced transcriptomic reprogramming in triple negative breast cancers
    Journal Article

    Kabeer, F.; Tran, H.; Andronescu, M.; Singh, G.; Lee, H.; Salehi, S.; Wang, B.; Biele, J.; Brimhall, J.; Gee, D.; more...
    Genome Biology (2024)

    Fulltext@MSK | Save
  • A phase 2 study of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma
    Journal Article

    Msaouel, P.; Sweis, R. F.; Bupathi, M.; Heath, E.; Goodman, O. B. Jr; Hoimes, C. J.; Milowsky, M. I.; Davis, N.; Kalebasty, A. R.; Picus, J.; more...
    European Urology Oncology (2024)

    Fulltext@MSK | Save